Supplementary Material*

Wilt TJ, Kaka AS, MacDonald R, et al. Remdesivir for adults with COVID-19. A living systematic review for American College of Physicians Practice Points. Ann Intern Med. 5 October 2020. [Epub ahead of print]. doi:10.7326/M20-5752

* This supplementary material was provided by the authors to give readers further details on their article. The material was reviewed but not copyedited.

Supplement Table 1. Search Strategies

Source	Strategy
MEDLINE and CENTRAL (Cochrane Central Trials Register)	1. exp Coronavirus/ or exp Coronavirus Infections/ 2. (nCoV or 2019-nCoV or ((new or novel or wuhan) adj3 coronavirus) or covid19 or covid-19 or SARS-CoV-2 or "Severe Acute Respiratory Syndrome Coronavirus 2").ti,ab,kw. 3. 1 or 2 4. (remdesivir or Veklury or GS-5734).ti,ab,kw. 5. 3 and 4
WHO Database	1. remdesivir or Veklury or GS-5734
NIH COVID-19 iSearch Portfolio	1. remdesivir or Veklury or GS-5734 Title/Abstract fields only, medRxiv
Journal Tables of Contents (New England Journal of Medicine, JAMA Network, The Lancet)	Keyword search: (remdesivir or Veklury or GS-5734)
Gilead Sciences, Inc. https://www.gilead.com/science-and-medicine/research	

Supplement Table 2. GRADE Approach to Rating the Certainty of Evidence

The GRADE approach to rating the certainty of evidence for randomized controlled trials is based on five reasons to possibly rate down the quality of evidence (1).	
Reason	**Consequence**
Limitations in study design or execution (risk of bias)	↓ 1 or 2 levels
Inconsistency of results	↓ 1 or 2 levels
Indirectness of evidence	↓ 1 or 2 levels
Imprecision	↓ 1 or 2 levels
Publication bias	↓ 1 or 2 levels

Supplement Table 3. Study Characteristics

Author, Year Country **Funding** **Risk of Bias**	**Intervention** **Comparator** **Inclusion/exclusion criteria** **Study Period/Length of Follow-up**	**Demographics**
Beigel 2020 (2) Adaptive Covid-19 Treatment Trial (ACTT-1) Multinational (60 sites, 45 in the US) Design: RCT Funding: Primarily government, other Risk of Bias: Low	Intervention: Remdesivir (n=541) 200 mg on day 1 followed by 100 mg on days 2–10 (or until hospital discharge or death) in single daily infusions Comparator: Placebo (n=522) Inclusion criteria: 18 years or older and meeting one of the following criteria suggestive of lower respiratory tract infection at enrollment: radiographic infiltrates by imaging study, peripheral oxygen saturation (SpO2) ≤94% on room air, or requiring supplemental oxygen, mechanical ventilation, or ECMO; no limit to duration of symptoms prior to enrollment; laboratory-confirmed SARS-CoV-2 infection as determined by a positive RT-PCR assay result from any respiratory specimen collected <72 hours prior to randomization (during the study, this criterion was modified due to limitations in testing capacity to also allow a RT-PCR positive specimen that was collected ≥72 hours prior to randomization if the site was unable to obtain a repeat sample and if the participant had progressive disease consistent with ongoing SARS-CoV-2 infection). Exclusion criteria: ALT or AST >5 times the upper limit of the normal range, impaired renal function as determined by calculating an eGFR or need for hemodialysis or hemofiltration, allergy to study product, pregnancy or breast-feeding, and anticipated discharge from hospital or transfer to another hospital within 72 hours of enrollment **Study Period/Length of Follow-up:** 29 days	N=1063 **Age (years, mean):** 59 **Gender (male):** 64% **Race/Ethnicity:** White 53% Black/African American 21% Asian 13% Latino (of any race) 23% **Time from symptom onset to randomization** Overall, median [IQR] 9 days [6-12] Remdesivir median [IQR] 9 days [6-12] Placebo median [IQR] 9 days [7-13] **Oxygen status on admission:** Percent on no oxygen 12% Percent on supplemental oxygen 40% Percent on non-invasive ventilation 19% Percent on invasive ventilation 26%

Author, Year Country **Funding** **Risk of Bias**	**Intervention** **Comparator** **Inclusion/exclusion criteria** **Study Period/Length of Follow-up**	**Demographics**
Wang 2020 (3) China Design: RCT Funding: Government, other Risk of Bias: Low	Intervention: Remdesivir (n=158; 2:1 ratio) 200 mg on day 1 followed by 100 mg on days 2–10 in single daily infusions Comparator: Placebo (n=79) Inclusion criteria: men and non-pregnant women with COVID-19, age at least 18 years, RT-PCR positive for SARS-CoV-2, pneumonia confirmed by chest imaging, oxygen saturation of 94% or lower on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or less, within 12 days of symptom onset Exclusion criteria: pregnancy or breast feeding; hepatic cirrhosis; ALT or AST >5 times the upper limit of the normal range; known severe renal impairment (estimated eGFR<30 mL/min per 1·73 m^2) or receipt of continuous renal replacement therapy, hemodialysis, or peritoneal dialysis; enrolment into an investigational treatment study for COVID-19 in the 30 days before screening **Study Period/Length of Follow-up:** 28 days	N=237 **Age (years, median):** Remdesivir 66 Placebo 64 **Gender (male):** Remdesivir 56% Placebo 65% **Race:** East Asian **Time from symptom onset to drug** Remdesivir median [IQR] 11 days [9-12] Placebo median [IQR] 10 days [9-12] **Oxygen status on admission:** Percent on no oxygen Remdesivir 0% Placebo 4% Percent on supplemental O_2 Remdesivir 82% Placebo 83% Percent on non-invasive ventilation Remdesivir 18% Placebo 12% Percent on invasive ventilation Remdesivir 0% Placebo 1%

Author, Year Country **Funding** **Risk of Bias**	**Intervention** **Comparator** **Inclusion/exclusion criteria** **Study Period/Length of Follow-up**	**Demographics**
Goldman 2020 (4) GS-US-540-5773 SIMPLE 1 55 hospitals around the world, including sites in the US, Italy, Spain, Germany, Hong Kong, Singapore, South Korea, and Taiwan. Design: Randomized, open-label, multi-center Phase 3 clinical trial Funding: Industry Risk of Bias: Moderate	Intervention 1: Remdesivir, 5-day course (n=200) 200 mg on day 1 followed by 100 mg on days 2–5 in single daily infusions Intervention 2: Remdesivir, 10-day course (n=197) 200 mg on day 1 followed by 100 mg on days 2–10 in single daily infusions Inclusion criteria: patients ≥ 18 years (at all sites), or aged ≥ 12 and < 18 years of age weighing ≥ 40 kg (where permitted according to local law) currently hospitalized with SARS-CoV-2 infection confirmed by PCR test ≤ 4 days before randomization; radiographic evidence of pulmonary infiltrates and peripheral capillary oxygen saturation (SpO2) ≤ 94% or requiring supplemental oxygen at screening Exclusion criteria: Pregnant or women who were breast feeding infants, ALT or AST >5 times the upper limit of the normal range, creatinine clearance < 50 mL/min using the Cockcroft-Gault formula for participants ≥ 18 years of age and Schwartz Formula for participants < 18 years of age; mechanically ventilated (including V-V ECMO) ≥ 5 days, or any duration of V-A ECMO; evidence of multiorgan failure; concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2 < 24 hours prior to study drug dosing; participant in any other clinical trial of an experimental treatment for COVID-19. **Study Period/Length of Follow-up:** 14 days (up to 30 days for adverse events)	N=397 **Age (years, median):** 5-day group 61 10-day group 62 **Gender (male):** 5-day group 60% 10-day group 68% **Race:** White 70% Black 11% Asian 11% Other 7% **Time from symptom onset to drug** Remdesivir 5-day median [IQR] 8 days [5-11] Remdesivir 10-day median [IQR] 9 days [6-12] **Oxygen status on admission:** Percent on no oxygen 14% Percent on supplemental oxygen 55% Percent on non-invasive ventilation 27% Percent on invasive ventilation 4%

Author, Year Country **Funding** **Risk of Bias**	**Intervention** **Comparator** **Inclusion/exclusion criteria** **Study Period/Length of Follow-up**	**Demographics**
Spinner 2020 (5) GS-US-540-5774 SIMPLE 2 105 sites in the US, France, Germany, Hong Kong, Italy, Republic of Korea, The Netherlands, Singapore, Spain, Switzerland, Taiwan and the United Kingdom Design: Randomized, open-label, multi-center Phase 3 clinical trial Funding: Industry Risk of Bias: Low	Intervention 1: Remdesivir, 5-day course (n=199) 200 mg on day 1 followed by 100 mg on days 2–5 in single daily infusions Intervention 2: Remdesivir, 10-day course (n=197) 200 mg on day 1 followed by 100 mg on days 2–10 in single daily infusions Comparator: Standard care (n=200) Inclusion criteria: ≥ 18 years (at all sites), or aged ≥ 12 and < 18 years of age weighing ≥ 40 kg (where permitted according to local law and approved by relevant review boards) currently hospitalized and requiring medical care for COVID-19; SARS-CoV-2 infection confirmed by PCR test ≤ 4 days before randomization; moderate COVID-19 pneumonia (peripheral capillary oxygen saturation (SpO_2) >94% on room air radiographic evidence of pulmonary infiltrates) Exclusion criteria: Women who were pregnant or breast feeding infants, ALT or AST >5 times the upper limit of the normal range; creatinine clearance < 50 mL/min using the Cockcroft-Gault formula for participants ≥ 18 years of age and Schwartz Formula for participants < 18 years of age; mechanically ventilated at screening; concurrent treatment or planned concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2; participation in any other clinical trial of an experimental treatment for COVID-19. **Study Period/Length of Follow-up:** 11 days (primary outcome); final assessment on day 28	**N=596 randomized (584 analyzed)** **Age (years, median):** 5-day group 58 10-day group 56 Standard care 57 **Gender (male):** 61% **Race:** White 58% Black 18% Asian 18% Other 7% Latino (of any race) 18% **Time from symptom onset to drug** Remdesivir 5-day median [IQR] 8 days [5-11] Remdesivir 10-day median [IQR] 8 days [5-11] **Oxygen status on admission:** Percent on no oxygen: 84% Percent on supplemental oxygen: 15% Percent on non-invasive ventilation: 1% Percent on invasive ventilation: 0%

ALT = alanine aminotransferase; AST = aspartate aminotransferase; ECMO = extracorporeal membrane oxygenation; eGFR = estimated glomerular filtration rate; IQR = interquartile range; RT-PCR = reverse transcription, polymerase-chain-reaction; SARS-CoV = Severe Acute Respiratory Syndrome Coronavirus-2 infection

Supplement Table 4. Outcomes A

Author, Year	Length of hospital stay		Time to recovery		Mortality		Recovery or Combined endpoint "Clinical Improvement"	
	Remdesivir	**Placebo**	**Remdesivir**	**Placebo**	**Remdesivir**	**Placebo**	**Remdesivir**	**Placebo**
Beigel 2020 (2) ACTT-1	NR	NR	Median (95% CI) 11 days [9 to 12]	Median (95% CI) 15 days [13 to 19]	14-day 5.9% (32/538) HR 0.70 [95% CI, 0.47 to 1.04] *Note: 2 subjects (1 in each group) died 15 days post-randomization* *28-day mortality is not reported in this preliminary analysis*	14-day 10.4% (54/521)	Day 29 Recovery * 62.1% (334/538) Recovery Rate Ratio 1.32 [CI, 1.12 to 1.55] *Recovery Mild/mod. Disease † 83.9% (52/62)* *Severe Disease ‡ 59.2% (282/476)*	Day 29 Recovery * 52.4% (273/521) *Recovery Mild/mod. Disease † 80.7% (46/57)* *Severe Disease ‡ 48.9% (227/464)*

Wang 2020 (3)	Median (IQR) 25 days [16 to 38] Difference 0.0 days [CI, -4.0 to 4.0]	Median (IQR) 24 days [18 to 36]	Time to Clinical Improvement Median (IQR) 21 days [13 to 28]	Time to Clinical Improvement Median (IQR) 23 days [15 to 28]	28-day 13.9% (22/158) ARD 1.1% [CI, -8.1 to 10.3]	28-day 12.8% (10/78)	Day 28 Clinical improvement § 65.2% (103/158) ARD 7.5% [CI, -5.7 to 20.7] Hazard ratio 1·23 [CI, 0·87 to 1·75]	Day 28 Clinical improvement § 57.7% (45/78)

Goldman 2020 (4) GS-US-540-5773 SIMPLE 1	**Remdesivir 5-day**	**Remdesivir 10-day**	**Remdesivir 5-day**	**Remdesivir 10-day**	**Remdesivir 5-day**	**Remdesivir 10-day**	**Remdesivir 5-day**	**Remdesivir 10-day**
	NR	NR	Median (IQR) 10 days [6 to 18] Hazard ratio 0.81 [CI, 0.64 to 1.04]	Median (IQR) 11 days [7 to not possible to estimate]	14-day 8.0% (16/200) P=.70	14-day 10.7% (21/197)	Day 14 Clinical recovery ‖ 64.5% (129/200) Baseline-adjusted ARD and p-value 6.3% [CI, -2.8 to 15.4]; P=.17 Clinical (≥2-point) improvement ¶ 64.5% (129/200) Baseline-adjusted ARD and P-value -6.5% [CI, -2.8 to 15.7]; P=.16	Day 14 Clinical recovery ‖ 53.8% (106/197) Clinical (≥2-point) improvement ¶ 54.3% (107/197)

Spinner 2020 (5)	**Remdesivir**	**Standard Care**	**Remdesivir**	**Standard Care**	**Remdesivir**	**Standard Care**	**Remdesivir**	**Standard Care**

GS-US-540-5774 SIMPLE 2 with standard care	NR	NR	Median (IQR) 5 day 6 (5-10) 10 day 8 (4-13)	Median (IQR) 7 (4-14)	11-day 5-day 0% (0/191) 10-day 1.0% (2/193) HR for 5-day vs. standard care 0.51 [CI, 0.09 to 2.80] HR for 10-day vs. standard care 0.76 [CI, 0.17 to 3.40]	11-day 2.0% (4/200)	Day 11 Recovery ‖ 5-day 73.8% (141/191) 10-day 68.4% (132/193) HR for 5-day vs. standard care 1.18 [CI, 0.96 to 1.45] HR for 10-day vs. standard care 1.11 [CI, 0.90 to 1.36] Clinical (≥2-point) improvement ¶ 5-day 70.2% (134/191) 10-day 65.3% (126/193) HR for 5-day vs. standard care 1.15 [CI, 0.93 to 1.42]	Day 11 Recovery ‖ 64.0% (128/200) Clinical (≥2-point) improvement ¶ 60.5% (121/200)

							HR for 10-day vs. standard care 1.16 [CI, 0.93 to 1.43]	

ARD = absolute risk difference; CI = confidence interval; HR = Hazard ratio; IQR = interquartile range; NR = not reported

* Defined by either discharge from the hospital or hospitalization extended for purposes of infection-control only with no medical needs.

† Mild/moderate disease was defined by a SpO2 >94% and respiratory rate <24 breaths per minute without supplemental oxygen requirement.

‡ Severe disease was defined as participants meeting one or more of the following criteria: requiring invasive or non-invasive mechanical ventilation, requiring supplemental oxygen, an SpO2 ≤94% on room air, or respiratory rate ≥24 breaths per minute.

§ Defined as a two-point reduction in patients' admission status on a six-point ordinal scale, or live discharge from the hospital, whichever came first. The six-point scale was as follows: death=6; hospital admission for extracorporeal membrane oxygenation or mechanical ventilation=5; hospital admission for noninvasive ventilation or high-flow oxygen therapy=4; hospital admission for oxygen therapy (but not requiring high-flow or non-invasive ventilation)=3; hospital admission but not requiring oxygen therapy=2; and discharged or having reached discharge criteria (defined as clinical recovery—ie, normalization of pyrexia, respiratory rate <24 breaths per minute, saturation of peripheral oxygen >94% on room air, and relief of cough, all maintained for at least 72 h)=1 within 28 days after randomization

‖ Patients achieved clinical recovery if they no longer required oxygen support and medical care or were discharged from the hospital (improvement from a baseline score of 2 to 5 to a score of 6 or 7).

¶ Clinical improvement was defined as an improvement of two or more points from baseline on a predefined seven-point scale consisting of the following categories: 1, death; 2, hospitalized, receiving invasive mechanical ventilation or ECMO; 3, hospitalized, receiving noninvasive ventilation or high-flow oxygen devices; 4, hospitalized, requiring low-flow supplemental oxygen; 5, hospitalized, not requiring supplemental oxygen but receiving ongoing medical care (related or not related to Covid-19); 6, hospitalized, requiring neither supplemental oxygen nor ongoing medical care (other than that specified in the protocol for remdesivir administration); and 7, not hospitalized.

Supplement Table 5. Outcomes B

Author, Year	Required invasive mechanical ventilation; Duration of invasive mechanical ventilation, days		Duration of oxygen support, days	
	Remdesivir	**Placebo**	**Remdesivir**	**Placebo**
Beigel 2020 (2) ACTT-1 Table S2 appendix	13.8% (63/434) at Day 15 visit; Duration NR	17.6% (72/410) at Day 15 visit; Duration NR	NR	NR
Wang 2020 (3)	8.2% (13/158) Median 7.0 days [4 to 16] Difference -4.0 days [-14.0 to 2.0]	12.8% (10/78) Median 15.5 days [6 to 21]	Median 19.0 days [11 to 30] Difference -2.0 days [-6.0 to 1.0]	Median 21.0 days [14 to 30.5]
Goldman 2020 (4) GS-US-540-5773 SIMPLE 1	**Remdesivir 5-day**	**Remdesivir 10-day**	**Remdesivir 5-day**	**Remdesivir 10-day**
	8.0% (16/200); Duration NR	16.8% (33/197); Duration NR	NR	NR
Spinner 2020 (5) GS-US-540-5774 SIMPLE 2 with standard care	**Remdesivir**	**Standard Care**	**Remdesivir**	**Standard Care**
	NR	NR	Time to Room Air Median (IQR) 5-day 5 (3-7) 10-day 4 (2-6) 6.3% (12/191) and 6.7% (13/193) required oxygen support on Day 1	6 (4-14) 11% (22/200) required oxygen support on Day 1

ECMO = extracorporeal membrane oxygenation; NR = not reported

Supplement Table 6. Viral Load

Author, Year Viral load definition	Pre		Post	
	Remdesivir	**Placebo**	**Remdesivir**	**Placebo**
Beigel 2020 (2) ACTT-1	NR	NR	NR	NR
Wang 2020 (3) ***Mean baseline viral load of nasopharyngeal and oropharyngeal swabs***	4.7 log_{10} copies/mL	4.7 log_{10} copies per mL	NR	NR
Upper respiratory tract specimens	*Estimated from graph* 3.7 log_{10} copies/mL	*Estimated from graph* 3.6 log_{10} copies/mL	*Estimated from graph* 0.6 log_{10} copies/mL	*Estimated from graph* 0.1 log_{10} copies/mL
Lower respiratory tract specimens	*Estimated from graph* 7.3 log_{10} copies/mL	*Estimated from graph* 6.4 log_{10} copies/mL	*Estimated from graph* 1.4 log_{10} copies/mL	*Estimated from graph* 0.0 log_{10} copies/mL
Goldman 2020 (4) GS-US-540-5773 SIMPLE 1	**Remdesivir 5-day**	**Remdesivir 10-day**	**Remdesivir 5-day**	**Remdesivir 10-day**
	NR	NR	NR	NR
Spinner 2020 (5) GS-US-540-5774 SIMPLE 2 with standard care	**Remdesivir**	**Standard Care**	**Remdesivir**	**Standard Care**
	NR	NR	NR	NR

NR = not reported

Supplement Table 7. Harms A (Based on Number of Subjects Reporting At Least 1 Event)

Author, Year	Serious AE		AE leading to drug withdrawal		Any AE	
	Remdesivir	**Placebo**	**Remdesivir**	**Placebo**	**Remdesivir**	**Placebo**
Beigel 2020 (2) ACTT-1	21.1% (114/541) *Study-related* 2 events	27.0% (141/522) *Study-related* 2 events	6.7% (36/541)	6.9% (36/522)	Non-serious 28.8% (156/541)	Non-serious 33.0% (172/522)
Wang 2020 (3)	18.1% (28/155) Grade 3 or 4 5.8% (9/155)	25.6% (20/78) Grade 3 or 4 12.8% (10/78)	11.6% (18/155)	5.1% (4/78)	65.8% (102/155) Grade 3 or 4 8.4% (13/155)	64.1% (50/78) Grade 3 or 4 14.1% (11/78)
Goldman 2020 (4) GS-US-540-5773 SIMPLE 1	**Remdesivir 5-day**	**Remdesivir 10-day**	**Remdesivir 5-day**	**Remdesivir 10-day**	**Remdesivir 5-day**	**Remdesivir 10-day**
	21.0% (42/200)	34.5% (68/197)	4.5% (9/200) P=.07	10.2% (20/197)	70.5% (141/200) P=.86 Grade ≥3 30% (60/200)	73.6% (145/197) Grade ≥3 43% (85/197)
Spinner 2020 (5) GS-US-540-5774 SIMPLE 2 with standard care	**Remdesivir**	**Standard Care**	**Remdesivir**	**Standard Care**	**Remdesivir**	**Standard Care**
	5-day 4.7% (9/191) 10-day 5.2% (10/193)	9.0% (18/200)	5-day 2.1% (4/191) 10-day 4.1% (8/193)	NA	5-day 51.3% (98/191) 10-day 58.5% (113/193) Grade ≥3 5-day 10.5% (20/191) 10-day 12.4% (24/193)	46.5% (93/200) Grade ≥3 12.0% (24/200)

AE = adverse event; NR = not reported

Supplement Table 8. Harms B (Based on Number of Subjects Reporting At Least 1 Event)

Author, Year	Respiratory failure or acute respiratory distress syndrome		Cardiopulmonary failure	
	Remdesivir	**Placebo**	**Remdesivir**	**Placebo**
Beigel 2020 (2) ACTT-1	Serious respiratory failure AEs" 5.2% (28/541) Respiratory distress 1.7% (9/541)	Serious respiratory failure AEs" 8.0% (42/522) Respiratory distress 1.9% (10/522)	NR	NR
Wang 2020 (3)	Respiratory failure or acute respiratory distress syndrome 10.3% (16/155) Grade 3 or 4 2.6% (4/155)	Respiratory failure or acute respiratory distress syndrome 7.7% (6/78) Grade 3 or 4 5.1% (4/78)	5.2% (8/155)	9.0% (7/78)
Goldman 2020 (4) GS-US-540-5773 SIMPLE 1	**Remdesivir 5-day**	**Remdesivir 10-day**	**Remdesivir 5-day**	**Remdesivir 10-day**
	6.0% (12/200)	10.7% (21/197)	NR	NR
Spinner 2020 (5) GS-US-540-5774 SIMPLE 2 with standard care	**Remdesivir**	**Standard Care**	**Remdesivir**	**Standard Care**
	NR	NR	NR	NR

AE = adverse event; NR = not reported

*Recurrence of COVID-19: Reported for one remdesivir patient

Supplement Table 9. Risk of Bias – Randomized Controlled Trials

Author, Year	Random sequence generation	Allocation concealment	Blinding*	Incomplete outcome data†	Selective outcome reporting‡	Overall Risk of Bias§
Beigel 2020 (2) ACTT-1	Low, adequate, permuted randomization sequence	Low, adequate, web-based	Low, patient, provider Follow-up safety and efficacy evaluations performed by blinded clinic staff	Low, one placebo patient and 3 remdesivir patients excluded due to no data after baseline.	No	Low
Wang 2020 (3) Note: trial stopped early	Low, adequate, permuted block randomization sequence	Low, adequate, centralized	Low, patient, provider	Low, one placebo patient withdrew consent, not in ITT analyses. Three remdesivir patients did not take drug and are not in the safety analyses	No	Low
Goldman 2020 (4) GS-US-540-5773 SIMPLE 1	Low, adequate, computer generated	Low, adequate, web-based	Open-label Outcome assessors were not blinded.	Low,2 patients in the 5-day group and 3 in the 10-day group not included in analyses (withdrawn or randomized in error)	No	Moderate based on imbalance between groups (patients randomly assigned to the 10-day group had significantly worse clinical status than those assigned to the 5-day group (P = 0.02)) and open label nature of study.
Spinner 2020 (5) GS-US-540-5774 SIMPLE 2 with standard care	Low, adequate, computer generated	Low, adequate, web-based	Open-label Outcome assessors were not blinded.	Low, 8 patients in the 5-day group and 4 in the 10-day group not included in	No	Low

				analyses (did not start treatment)		

ITT = intent-to-treat

* For the open-label trial, blinding of study participants and study personnel was not feasible. This element was not considered in rating overall risk of bias.

† Incomplete outcome data was rated high if more than 10% of participants randomized were not included in the analyses.

‡ Selective reporting was determined by comparing reported outcomes with outcomes specified in the Methods section. If a protocol paper was available, reported outcomes were compared with outcomes specified in the protocol.

§ Studies were rated low risk of bias if at least 3 elements were rated low and no additional elements were rated high. Studies were rated High risk of bias if at least 2 elements were rated high risk of bias. All other studies were rated Moderate risk of bias.

Supplement Table 10. COVID-19 Disease Severity

COVID-19 Disease Severity	NIH COVID-19 Treatment Guidelines (6)	WHO Clinical Management of COVID-19 (7)	Food and Drug Administration (FDA) (8)	Included Studies in Evidence Report
Asymptomatic or Presymptomatic	Individuals who test positive for SARS-CoV-2 by virologic testing using a molecular diagnostic (e.g., polymerase chain reaction) or antigen test, but have no symptoms.	**NA**	Positive testing by standard reverse transcription polymerase chain reaction (RT-PCR) assay or equivalent test; no symptoms.	**NA**
Mild	Individuals who have any of the various signs and symptoms of COVID 19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnea, or abnormal chest imaging.	Symptomatic patients meeting the case definition for COVID-19 without evidence of viral pneumonia or hypoxia.	Positive testing by standard RT-PCR assay or equivalent test; symptoms of mild illness with COVID-19 that could include fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, without shortness of breath or dyspnea; no clinical signs indicative of Moderate, Severe, or Critical Severity	**ACTT-1 (1):** Mild/Moderate disease: confirmed COVID-19 positive and hospitalized with radiographic infiltrates by imaging, SpO_2 >94% and respiratory rate <24 breaths per minute without supplemental oxygen. Mild not defined. Results for Mild not provided.

COVID-19 Disease Severity	NIH COVID-19 Treatment Guidelines (6)	WHO Clinical Management of COVID-19 (7)	Food and Drug Administration (FDA) (8)	Included Studies in Evidence Report
Moderate	Individuals who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (SpO2) ≥94% on room air at sea level.	Adolescent or adult with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) but no signs of severe pneumonia, including SpO_2 ≥90% on room air OR Child with clinical signs of non-severe pneumonia (cough or difficulty breathing + fast breathing and/or chest indrawing) and no signs of severe pneumonia.	Positive testing by standard RT-PCR assay or equivalent testing; symptoms of moderate illness with COVID-19, which could include any symptom of mild illness or shortness of breath with exertion; clinical signs suggestive of moderate illness with COVID-19, such as respiratory rate ≥20 breaths per minute, saturation of oxygen (SpO_2) >93% on room air at sea level, heart rate ≥90 beats per minute; no clinical signs indicative of Severe or Critical Illness	**ACTT-1 (1):** Mild/Moderate disease: confirmed COVID-19 positive and hospitalized with radiographic infiltrates by imaging, SpO_2 >94% and respiratory rate <24 breaths per minute without supplemental oxygen. Moderate not further defined. Results for Moderate not provided. **SIMPLE 2** (4): Moderate disease: confirmed COVID-19 positive and hospitalized with radiographic evidence of pulmonary infiltrates and oxygen saturation >94% on room air.

COVID-19 Disease Severity	NIH COVID-19 Treatment Guidelines (6)	WHO Clinical Management of COVID-19 (7)	Food and Drug Administration (FDA) (8)	Included Studies in Evidence Report
Severe	Individuals who have respiratory frequency >30 breaths per minute, SpO_2 <94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO_2/FiO_2) <300 mmHg, or lung infiltrates >50%.	Adolescent or adult with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) plus one of the following: respiratory rate >30 breaths/min; severe respiratory distress; or SpO_2 <90% on room air OR Child with clinical signs of pneumonia (cough or difficulty in breathing) + at least one of the following: 1) Central cyanosis or SpO_2 <90%; severe respiratory distress (e.g. fast breathing, grunting, very severe chest indrawing); general danger sign: inability to breastfeed or drink, lethargy or unconsciousness, or convulsions. 2) Fast breathing (in breaths/min): <2 months: ≥60; 2–11 months: ≥50; 1–5 years: ≥40.	Positive testing by standard RT-PCR assay or an equivalent test; symptoms suggestive of severe systemic illness with COVID-19, which could include: any symptom of moderate illness or shortness of breath at rest, or respiratory distress; clinical signs indicative of severe systemic illness with COVID-19, such as respiratory rate ≥30 per minute, heart rate ≥125 per minute, SpO_2 ≤93% on room air at sea level or PaO_2/FiO_2 <300; no criteria for Critical Severity. Remdesivir Emergency Use Authorization Criteria: Hospitalized with severe disease defined as patients with an oxygen saturation ≤94% on room air or requiring supplemental oxygen or mechanical ventilation or requiring extracorporeal membrane oxygenation (ECMO).	**Wang (2), ACTT-1 (1), SIMPLE 1 (3):** Hospitalized patients meeting one of more of the following criteria: radiographic infiltrates by imaging or clinical assessment and an oxygen saturation ≤94% on room air or tachypnea (respiratory rate >24 breaths per minute without supplemental oxygen) or requiring supplemental oxygen or mechanical ventilation

COVID-19 Disease Severity	NIH COVID-19 Treatment Guidelines (6)	WHO Clinical Management of COVID-19 (7)	Food and Drug Administration (FDA) (8)	Included Studies in Evidence Report
Critical	Individuals who have respiratory failure, septic shock, and/or multiple organ dysfunction.	Individuals who have respiratory failure, septic shock, and/or multiple organ dysfunction	Positive testing by standard RT-PCR assay or equivalent test; evidence of critical illness, defined by at least one of the following: respiratory failure defined based on resource utilization requiring at least one of the following: endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates >20 L/min with fraction of delivered oxygen ≥0.5), noninvasive positive pressure ventilation, ECMO, or clinical diagnosis of respiratory failure (i.e., clinical need for one of the preceding therapies, but preceding therapies not able to be administered in setting of resource limitation); shock (defined by systolic blood pressure <90 mm Hg, or diastolic blood pressure <60 mm Hg or requiring vasopressors); multi-organ dysfunction/failure.	ACTT-1: Not defined as “critical” but ACTT-1 included and provided recovery outcomes for patients requiring invasive mechanical ventilation or ECMO.

Supplemental Table References

1. Schünemann H, Brożek J, Guyatt G, et al, eds. GRADE handbook for grading quality of evidence and strength of recommendations. GRADE Working Group; 2013. Available from: https://gdt.gradepro .org/app/handbook/handbook.html. Accessed 2 June 2020.
2. Beigel JH, Tomashek LD, Dodd AK, et al.. Remdesivir for the treatment of Covid-19-preliminary report. *N Engl J Med.* 2020. DOI: 10.1056/NEJMoa2007764.
3. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet.* 2020;395(10236):1569-1578.
4. Goldman JD, Lye DCB, Hu DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. *N Engl J Med.* 2020. DOI: 10.1056/NEJMoa2015301.
5. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. Published online August 21, 2020. doi:10.1001/jama.2020.16349
6. NIH COVID-19 Treatment Guidelines. Available from: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf. Accessed 24 July 2020.
7. WHO Clinical Management of COVID-19. Available from: https://www.who.int/publications/i/item/clinical-management-of-covid-19. Accessed 24 July 2020.
8. US Food and Drug Administration. Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of Remdesivir (GS-5734™). Available from: https://www.fda.gov/media/137926/download. Accessed 24 July 2020.